Karnataka's Nandini holds strong as one of India's top food & beverage brands in 2025 rankings: Report
Nandini, the flagship dairy brand of the Karnataka Milk Federation (KMF), has once again cemented its position among India's elite in the food and beverage space. In the latest 2025 rankings released by global brand valuation firm Brand Finance, Nandini retained its fourth spot, standing tall alongside industry heavyweights like Amul, Mother Dairy, Britannia, and Dabur, news agency PTI reported. Customers at a Nandini milk shop in Bengaluru.(PTI)
ALSO READ | Fresh row erupts over Amul kiosks at Bengaluru metro stations
"In its latest report, Nandini has demonstrated remarkable progress, climbing from 43 in 2024 to 38 in 2025 among the Top 100 Most Valuable Indian Brands. The brand's valuation rose to USD 1,079 million, reflecting an impressive increase of USD 139 million in brand value over the previous year," the Karnataka Milk Federation (KMF) said in a statement accessed by news agency PTI.
KMF expressed pride in Nandini's continued presence among the top-tier, with the brand trailing only behind Amul (#1), Mother Dairy (#2), and Britannia (#3), while staying ahead of several other major players including Dabur (#5).
ALSO READ | DK Shivakumar says Nandini will get space in 8 metro stations, amid political row over Amul outlets in Bengaluru
These rankings, which reflect not just financial value but also intangible factors like consumer trust, market share, goodwill and brand loyalty, serve as a benchmark for brand strength and influence. A high position on this list is a signal of enduring consumer confidence and competitive edge, the report stated.
Nandini's consistent climb in valuation highlights its growing resonance with consumers, particularly in South India, reinforcing its reputation for quality and reliability in a crowded marketplace.
ALSO READ | From Nandini milk to Namma Metro: How Bengaluru's cost of living has skyrocketed in a year
"We extend our sincere gratitude to our valued consumers, dedicated farmers, trusted partners, and committed teams. Your continued trust and unwavering support have been the driving force behind Nandini's growth and recognition. We remain steadfast in our commitment to delivering value, nourishment, and reliability--every single day. Together, we will continue to strengthen Nandini's legacy and reach new milestones," KMF's MD B Shivaswamy said, as quoted by the agency.
(With inputs from PTI)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
First Post
30 minutes ago
- First Post
The emerging divide in US-Japan relations
The US–Japan alliance is considered the most enduring partnership in the Indo-Pacific. However, recent developments indicate a growing unevenness in this crucial bilateral relationship. Once a predictable and resilient alliance now appears misaligned, particularly in expectations surrounding defence spending, diplomatic access, and international crises. Japan's anxieties resurfaced with the return of a Donald Trump administration, although initial gestures offered reassurance. Prime Minister Shigeru Ishiba, despite not having a prior personal relationship with Donald Trump, was among the first world leaders invited to the White House. This early outreach mirrored the treatment of Indian Prime Minister Narendra Modi. By contrast, the Australian Prime Minister was kept waiting and, even after re-election, has yet to be hosted in Washington. For Japan, this suggested that they might successfully recalibrate ties with Washington. Growing inconsistencies in US demands and Japan's limited diplomatic access to key American officials are causing unease in Tokyo, particularly given the Ishiba administration's relative inexperience. STORY CONTINUES BELOW THIS AD There are three clear signs of emerging strain. First, the US appears to be making broad demands on its allies in Europe and Asia regarding defence spending. The recently concluded NATO Summit in The Hague focused almost exclusively on persuading member states to raise defence spending to 5 per cent of GDP. While this was directed at NATO members, similar expectations are now surfacing in US dealings with Indo-Pacific partners like Japan, Korea and Australia. In fact, Japan's Prime Minister Ishiba declined an invitation to attend the NATO summit, despite a recent tradition of Japanese PMs participating in the post-Ukraine context. This absence was interpreted as a deliberate signal that Tokyo does not wish to be drawn into the same defence-spending framework that NATO members have accepted. Japanese officials have reportedly encountered mixed messaging from Washington. On one hand, Japan is being informally asked to raise its defence spending to 3 per cent of GDP, a significant increase from its current level of 1.8 per cent, with a planned rise to 2 per cent by 2027. On the other hand, US interlocutors are framing this expectation as a part of trade negotiations, linking it to tariff reductions. This dual messaging is complicating Japan's internal policy environment. Tokyo wants such increases to be seen as sovereign decisions, not concessions made under US pressure, particularly with Upper House elections looming in July. Ishiba is wary of appearing weak or reactive in the face of American demands. A second sign of strain lies in the way US officials are extending NATO-style expectations to Indo-Pacific allies. During the Shangri-La Dialogue, US defence officials suggested that Australia should aim for 3.5 per cent of GDP in defence spending. The same figure is now increasingly being floated in Washington's dealings with Tokyo. STORY CONTINUES BELOW THIS AD This recalibration appears to stem from people like Elbridge Colby, Under Secretary of Defence for Policy. Japanese officials reportedly find it difficult to engage with Colby's office, which they view as pushing unrealistic and uncoordinated demands. Complicating matters, is confusion in Tokyo about whether the 5 per cent NATO target applies to Indo-Pacific allies, 3.5 per cent for defence and 1.5 per cent for infrastructure resilience, which Japan may find more manageable than significantly raising direct defence outlays. The NATO-IndoPacific4 communique is unclear on this. The US justifies these expectations by framing them in the context of preparing for a possible Taiwan crisis, which Washington believes could be triggered by China by 2027. However, the abruptness and unilateral nature of these expectations are generating friction rather than fostering alignment. Japan feels cornered by demands that neither respect its political sensitivities nor offer strategic clarity. Reflecting this discontent, Tokyo has postponed the US–Japan '2+2' ministerial meeting between their foreign and defence ministers, originally scheduled to coincide with the upcoming Quad Foreign Ministers' Meeting in July beginning. While Japan remains committed to participating in the Quad event, it has declined to hold the bilateral dialogue at this time. Tokyo insists it prefers to wait until after the July 20 Upper House elections, when Ishiba hopes for a stronger domestic mandate. Observers in both countries doubt this will significantly alter Washington's expectations or attitude. STORY CONTINUES BELOW THIS AD Another manifestation of unevenness lies in Japan's cautious stance on US military actions. Japan has not explicitly supported the US attack on Iranian nuclear facilities, despite its alliance obligations. Ishiba remarked, 'It is difficult for Japan to make a definitive legal evaluation at this point.' Japan agrees that Iran must be prevented from acquiring nuclear weapons but is reluctant to condone an action lacking United Nations authorisation. For a country that places strong emphasis on international law, Japan fears that overt support for legally questionable military strikes could set dangerous precedents. This is especially relevant given the risk of China or North Korea engaging in similar actions in Japan's neighbourhood. Japan's current reticence is different from its past behaviour. In 2017, when the US struck Syria in response to chemical weapons use, then Prime Minister Shinzo Abe expressed understanding, albeit without giving outright support. In 2019, following attacks on oil tankers in the Strait of Hormuz, the US asked allies to join a naval coalition. Japan delayed participation for months and eventually sent its Self-Defence Forces independently, avoiding association with the US-led effort. STORY CONTINUES BELOW THIS AD Japan's nuanced diplomacy reflects its effort to balance alliance solidarity with its national legal and economic considerations, particularly its better relations with Iran and its dependence on stable energy imports. The inconclusive Trump-Ishiba meeting on the sidelines of the G7 taught Japan that doing more on defence is not getting it leeway on trade tariffs. Strategic Mistrust Growing? In sum, the emerging unevenness in US–Japan relations stems from several sources: inconsistent and opaque US demands, lack of diplomatic access to key American policymakers, pressure to commit to steep defence increases, and divergent interpretations of international law. These issues are further exacerbated by a sense in Tokyo that Washington's strategic messaging lacks coordination and is poorly timed with Japan's domestic political calendar. The Ishiba administration appears intent on managing the alliance with caution and asserting Japan's strategic autonomy where possible. Yet the reality remains that alliance management under Trump 2.0 is proving more complicated than anticipated. Japan may be unwilling to say 'no', but it is increasingly finding ways to say 'not yet'. STORY CONTINUES BELOW THIS AD As regional instability intensifies and Washington raises the stakes in its strategic competition with China, how the US and Japan recalibrate their expectations of each other may well determine the future balance of power in the Indo-Pacific. The author is a former ambassador to Germany, Indonesia, Ethiopia, ASEAN and the African Union. He tweets @AmbGurjitSingh. Views expressed in the above piece are personal and solely those of the author. They do not necessarily reflect Firstpost's views.
&w=3840&q=100)
Business Standard
37 minutes ago
- Business Standard
Indian pharma eyes US gains as $63.7 bn patent cliff nears: Analysts
The Indian pharmaceutical industry is poised to benefit from a major wave of patent expiries in the US, with small-molecule drugs worth $63.7 billion expected to go off-patent between 2025 and 2029—a 65 per cent increase over the previous five years. Combined with a broader Loss of Exclusivity (LoE) opportunity across the US and EU projected to reach $180 billion by 2035, this marks a significant opening for Indian drugmakers, according to a report by Antique Stock Broking Limited. This shift is expected to spur a rise in generic launches, particularly benefiting Indian players with emerging US operations and expertise in complex generics. Firms such as Alembic Pharmaceuticals and Shilpa Medicare, which have smaller US footprints, and larger players like Cipla and Lupin, which have invested early in differentiated products such as injectables and respiratory therapies, are seen as well positioned to gain market share. With global majors like Teva, Viatris and Sandoz having closed dozens of manufacturing sites since 2018, Indian companies are stepping in to fill the supply gap. However, the opportunity is unfolding amid growing strategic discipline. Filings of Abbreviated New Drug Applications (ANDAs) in the US declined 25 per cent year-on-year. FY25 filings are projected to close around 550—down from 740 in FY24 and 857 in FY22. This signals a pivot from volume to portfolio quality, regulatory compliance and margin protection. Commenting on this shift, Nilaya Varma, Group CEO and Co-founder of Primus Partners, said, 'India's pharma exports have grown from $15 billion in 2013–14 to nearly $28 billion in a decade. With 750+ USFDA-approved plants and rising strength in complex generics and biosimilars, India is primed to lead the next wave of affordable, high-quality medicines. Tapping the $180 billion LoE opportunity will require continued focus on compliance and quality systems.' Regulatory headwinds are also easing. The share of US FDA inspections resulting in Official Action Indicated (OAI) for Indian firms has fallen from 19 per cent in 2013 to 9 per cent in 2023. Companies like Cipla are further de-risking their US supply chains by adopting multi-site manufacturing and digital quality systems. Cipla, which holds a robust US portfolio of 284 ANDA and NDA filings—175 of which are approved and 73 under review—is focusing on commercialisation-ready products, including PEPFAR-approved generics. The company is betting on complex respiratory and injectable therapies to drive growth. Pharma major Lupin, which continues to benefit globally from its blockbuster autoimmune biologic Etanercept, plans to finalise its US commercialisation strategy closer to the drug's 2029 patent expiry. Meanwhile, Sun Pharma, despite offering a conservative FY26 outlook amid global macro uncertainties, is expanding its oncology pipeline. Its recently acquired UNLOXCYT (cosibelimab) is expected to significantly contribute to US revenues. The company noted that Keytruda's upcoming patent expiry was already factored into the acquisition. UNLOXCYT targets only one of Keytruda's multiple indications, and Sun remains confident in its potential to become a meaningful contributor to its US specialty business. In parallel, Sun is also strengthening its immunotherapy portfolio through a global licensing agreement with Philogen.
News18
38 minutes ago
- News18
Meesho IPO: Shareholders Approve Rs 4,500 Crore Fundraise Via Public Issue
Last Updated: Meesho has officially changed its name from Fashnear Technologies Private Limited to Meesho Private Limited, ahead of IPO launch. Meesho IPO: The way for the launch of Meesho IPO has been cleared with the approval of its shareholders for a plan to raise Rs 4,500 crore ($500 million) through a fresh issue of equity shares. In the filing with Registrar of Companies, Meesho announced that the resolution was passed during an Extraordinary General Meeting on June 25, 2025. Additionally, the shareholders approved the designation of co-founder Vidit Aatrey as chairman, managing director, and CEO. It is part of Meesho's board rejig ahead of the launch of its IPO. Meesho is reportedly expected to file Draft Red Herring Prospectus (DRHP) in the coming months under the confidential route, as MoneyControl reported earlier. The company is planning to raise a total of around Rs 8,500 crore ($1 billion) through a mix of primary capital and an offer for sale (OFS). Earlier, Meesho shifted the headquarters to India as part of its public listing plan. Meesho mergered its Delaware-based entity Meesho INC. with its Indian arm. Meesho has officially changed its name from Fashnear Technologies Private Limited to Meesho Private Limited, as per a certificate of incorporation issued by the Ministry of Corporate Affairs on May 13. The name change, effective from May 13, 2025, aligns with Meesho's strategic focus on strengthening its brand identity as a leading e-commerce platform in India. It reflects Meesho's evolution into a comprehensive online marketplace. The company will now begin the process for its IPO, though the timeline for the listing has not been disclosed. While Prosus and SoftBank jointly hold around 22 percent of Meesho, this stake is relatively lower compared to the combined ownership of Elevation Capital and Peak XV Partners, the two largest investors in the e-commerce startup. Meesho's revenue surged from Rs 3,240 crore in FY22 to Rs 5,735 crore in FY23 and further to Rs 7,615 crore in FY24. At the same time, its net losses have dramatically reduced from Rs 3,248 crore in FY22 to just Rs 305 crore in FY24, highlighting its improved financial health. First Published:
